Primary Clinical Study on Nimotuzumab with 3D-CRT and Chemotherapy for Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma
-
摘要:
目的 探讨尼妥珠单抗联合同期三维适形放疗(3D-CRT)及化疗治疗Ⅲ、ⅣA期鼻咽癌的疗效及不良反应。 方法 经组织病理确诊的Ⅲ、ⅣA期(2008分期)鼻咽癌初诊患者63例随机分为对照组(33例)和治疗组(30例), 均采用3D-CRT及同期和序贯紫杉醇顺铂方案化疗, 治疗组每周一放疗前行尼妥珠单抗100mg治疗, 共6~7次。 结果 放疗结束后2个月原发灶CR率、颈部淋巴结CR率治疗组分别为100.0%、96.7%, 明显高于对照组的81.8%及75.8%(P均 < 0.05), 放疗后1年局部控制率、无转移生存率在治疗组及对照组分别达到100.0%vs.89.3%、95.5%vs.82.1%(P > 0.05), 两组主要不良反应为放射性咽喉炎、放射性皮炎和恶心呕吐、白细胞减少、疲乏等, 耐受性较好。治疗组发生3度以上放射性咽喉炎(P < 0.05)、放射性皮炎(P > 0.05)较对照组偏高。 结论 尼妥珠单抗联合3D-CRT及紫杉醇及顺铂同期及序贯化疗治疗局部晚期鼻咽癌, 可提高近期完全缓解率及局部控制率, 耐受性较好, 远期生存率有待进一步观察研究。 Abstract:Objective To determine the safety and tolerability ofnimotuzumab, a humanized anti-epidermal growth factor receptor monoclonal antibody, in combination with three-dimensional conformal radiotherapy (3D-CRT) and chemotherapy for locoregionally advanced nasopharyngeal carcinoma. Methods A total of 63 patients with stages III-IVA nasopharyngeal carcinoma were enrolled and divided into two groups: a research group with 30 patients and a control group with 33 patients. All patients were treated with 3D-CRT as well as concurrent and sequential chemotherapy with paclitaxel and cisplatin. Patients in the research group were intravenously administered 100 mg of nimotuzumab weekly for 6 weeks to 7 weeks before radiotherapy. Results Two months after radiotherapy, the complete response rates (CR) of nasopharyngeal cancer and cervix lymph nodes were 100% and 96.7%, respectively, in the research group, and 81.8% and 75.8%, respectively, in the control group. A significant difference was indicated (P < 0.05). The 1-year locoregional control and distant metastasis-free survival rates were 71.4% and 95.5%, in the control group and the research group, respectively. No significant difference was indicated (P=0.068 > 0.05). Major side effects included oral mucositis, actinodermatitis, neutropenia, nausea, vomiting, and fatigue; however, these effects were tolerable. A significant difference was found in the frequency of grade 3 to grade 4 acute oral mucositis between the groups (P < 0.05). Conclusion Nimotuzumab combined with 3D-CRT and paclitaxel and cisplatin chemotherapy can improve the CR on locoregionally advanced nasopharyngeal carcinoma, with mild to moderate side effects. Further study may be conducted to observe the distant metastasis-free survival rates. -
Key words:
- Nasopharyngeal carcinoma /
- Radiotherapy /
- Nimotuzumab /
- Chemotherapy /
- Epidermal Growth Factor Receptor
-
表 1 两组病例一般资料比较 例
Table 1. Analysis of general data in two groups
表 2 两组患者的疗效观察
Table 2. Comparison of therapeutic efficacy between the groups
表 3 两组不良反应比较 例
Table 3. Comparison of adverse effects between the groups
-
[1] 王树森, 管忠震, 向燕群, 等. 鼻咽癌组织中EGFR和p-ERK蛋白表达的检测及意义[J]. 中华肿瘤杂志, 2006, 28(1): 28-31. doi: 10.3760/j.issn:0253-3766.2006.01.008 [2] Modjtahedi H, Essapen S. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities[J]. Anticancer Drugs, 2009, 20(10): 851-855. doi: 10.1097/CAD.0b013e3283330590 [3] Talavera A, Friemann R, Gomez-Puerta S, et al. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks lig and binding while permitting the active receptor conformation[J]. Cancer Res, 2009, 69(14): 5851-5859. doi: 10.1158/0008-5472.CAN-08-4518 [4] 殷蔚伯, 余子豪, 徐国镇, 等, 主编. 肿瘤放射治疗学[M]. 第四版. 北京: 中国协和医科大学出版社, 2008: 578-1351. [5] Sundvall M, Karrila A, Nordberg J, et al. EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma[J]. Expert Opin Emerg Drugs, 2010, 15(2): 185-201. doi: 10.1517/14728211003716442 [6] Loeffler-Ragg J, Schwentner I, Sprinzl GM, et al. EGFR inhibition as a therapy for head and neck squamous cell carcinoma[J]. Expert Opin Investig Drugs, 2008, 17(10): 1517-1531. doi: 10.1517/13543784.17.10.1517 [7] Ramakrishnan MS, Eswaraiah A, Crombet T, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin[J]. Mabs, 2009, 1(1): 41-48. doi: 10.4161/mabs.1.1.7509 [8] Diaz Miqueli A, Rolff J, Lemm M, et al. Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies[J]. Br J Cancer, 2009, 100(6): 950-958. doi: 10.1038/sj.bjc.6604943 [9] Rojo F, Gracias E, Villena N, et al. Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a sendo foundation study[J]. Clin Cancer Res, 2010, 16(8): 2474-2482. doi: 10.1158/1078-0432.CCR-09-3042 [10] 汪洋, 潘力, 毛颖, 等. 尼妥珠单抗联合放疗加同期替莫唑胺治疗高分级胶质瘤的初步研究[J]. 中国癌症杂志, 2009, 19(11): 856-860. doi: 10.3969/j.issn.1007-3639.2009.11.010 [11] Strumberg D, Schultheis B, Scheulen ME, et al. Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer[J]. Int J Clin Pharmacol Ther, 2010, 48(7): 473-475. doi: 10.5414/CPP48473 [12] Choi HJ, Sohn JH, Lee CG, et al. A phase I study of nimotuzumab in combination with radiotherapy in stages IIB-IV non-small cell lung cancer unsuitable for radical therapy: Korean results[J]. Lung Cancer, 2011, 71(1): 55-59. doi: 10.1016/j.lungcan.2010.04.010 [13] Rodríguez MO, Rivero TC, del Castillo Bahi R, et al. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck[J]. Cancer Biol Ther, 2010, 9(5): 343-349. doi: 10.4161/cbt.9.5.10981 [14] Ledón N, Casacó A, Casanova E, et al. Comparative analysis of binding affinities to epidermal growth factor receptor of monoclonal antibodies nimotuzumab and cetuximab using different experimental animal models[J]. Placenta, 2011, 32(7): 531-534. doi: 10.1016/j.placenta.2011.04.008 [15] Pérez-Soler R, Delord JP, Halpern A, et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum[J]. Oncologist, 2005, 10(5): 345-356. doi: 10.1634/theoncologist.10-5-345 [16] 黄晓东, 易俊林, 高黎, 等. 抗表皮生长因子受体单克隆抗体h-R3联合放疗治疗晚期鼻咽癌的Ⅱ期临床研究[J]. 中华肿瘤杂志, 2007, 29(3): 197-200. doi: 10.3760/j.issn:0253-3766.2007.03.009 [17] 骆竹媚, 杨玉琼, 张洪, 等. 西妥昔单抗联合放化疗治疗中晚期鼻咽癌的临床观察[J]. 临床肿瘤学杂志, 2010, 15(2): 157-159. https://www.cnki.com.cn/Article/CJFDTOTAL-LCZL201002019.htm -
点击查看大图
表(3)
计量
- 文章访问数: 94
- HTML全文浏览量: 3
- PDF下载量: 1
- 被引次数: 0
下载:
